Nykode Therapeutics to Regain Control of VB10.NEO Program

07 Nov 2024 23:25 CET

Oslo, Norway, November 7, 2024 – Nykode Therapeutics ASA (OSE: NYKD), a
clinical-stage biopharmaceutical company dedicated to the discovery and
development of novel immunotherapies, today announced that it has received
notification from Genentech, a member of the Roche group, of its decision to
terminate the collaboration and licensing agreement for Nykode’s VB10.NEO cancer
vaccine program.

With this notice, the existing collaboration and licensing agreement signed
September 2020 will terminate effective January 6, 2025 and Nykode will regain
control of VB10.NEO and its intellectual property portfolio along with rights to
license the program. Nykode is not required to refund any upfront payments or
make any future payments to Genentech on the termination.

“We remain confident in the clinical data generated so far and the continued
potential of our personalized cancer vaccine VB10.NEO, and will determine the
optimal path forward for the program, including potential new partnerships”,
said Michael Engsig, Chief Executive Officer of Nykode Therapeutics.

Nykode plans to host a webcast tomorrow morning CET to provide further details
and answer questions about this development. Information regarding the time, and
access details for the webcast will be shared in a subsequent announcement.


About VB10.NEO
VB10.NEO is a proprietary individualized neoantigen vaccine in development for
the treatment of locally advanced or metastatic solid tumors. The vaccine is
designed to be produced on-demand according to the neoantigen profile of an
individual patient. Neoantigens are proteins generated by tumor-specific
mutations not present in normal tissues and are thus an attractive target for
cancer immunotherapy as they may be recognized as foreign by the immune system.
VB10.NEO has been evaluated in multiple indications in two clinical trials. It
has been shown to be generally well tolerated and with an ability to generate
uniquely broad patient- and tumor-specific long-lasting immune responses.

About Nykode Therapeutics
Nykode Therapeutics is a clinical-stage biopharmaceutical company dedicated to
the discovery and development of novel immunotherapies with a focus on the
treatment of cancer and autoimmune diseases. Nykode’s modular vaccine technology
specifically targets antigens to antigen presenting cells (APC), employed with
their cancer vaccines to induce a broad, strong and long-lasting antigen
specific immune response, which correlates with clinical responses in cancer
patients.

Nykode’s lead product candidates are VB10.16, a therapeutic vaccine for the
treatment of HPV16 induced malignancies, which demonstrated favorable safety and
efficacy results from its Phase 2 trial for the treatment of cervical cancer.
VB10.16 is being expanded into multiple trials for treatment of head and neck
cancer and cervical cancer. VB10.NEO, an individualized cancer neoantigen
vaccine, is being investigated in a trial with more than 10 different
indications.

The Company’s partnerships include a multi-target collaboration with Regeneron
in oncology and infectious diseases.

Nykode is also utilizing its APC-targeted technology to create an inverse
vaccine platform for the potential use in autoimmune disorders, organ transplant
rejections, anti-drug antibody reactions and allergy.

Nykode Therapeutics’ shares are traded on the Oslo Stock Exchange (OSE: NYKD).
Further information about Nykode Therapeutics can be found at
http://www.nykode.com.


Forward-looking statements for Nykode Therapeutics
This announcement and any materials distributed in connection with this
announcement may contain certain forward-looking statements. By their nature,
forward-looking statements involve risk and uncertainty because they reflect the
company's current expectations and assumptions as to future events and
circumstances that may not prove accurate. A number of material factors could
cause actual results and developments to differ materially from those expressed
or implied by these forward-looking statements.


Contact for Nykode Therapeutics ASA:
Alexandra Deschner, Head of IR
Nykode Therapeutics ASA
IR@nykode.com

Nykode Therapeutics ASA
Oslo Science Park
Gaustadalléen 21
N-0349 Oslo, Norway


This information is considered to be inside information pursuant to the EU
Market Abuse Regulation and is subject to the disclosure requirements pursuant
to Section 5-12 the Norwegian Securities Trading Act. This stock exchange
announcement was published by Harald Gurvin, CFO at Nykode Therapeutics ASA, on
November 7, 2024 at 23:25 CET.

More information:
Access the news on Oslo Bors NewsWeb site

631666_241107_VB10.NEO update_FINAL.pdf